Journal article
Low molecular weight heparins and heparinoids
Abstract
Several low molecular weight (LMW) heparin preparations, including dalteparin, enoxaparin and nadroparin, as well as the heparinoid danaparoid sodium, are approved for use in Australia. LMW heparins are replacing unfractionated heparin for the prevention and treatment of venous thromboembolism and the treatment of non-ST-segment-elevation acute coronary syndromes. The advantages of LMW heparins over unfractionated heparin include a longer …
Authors
Eikelboom JW; Hankey GJ
Journal
The Medical Journal of Australia, Vol. 177, No. 6, pp. 379–383
Publisher
Wiley
Publication Date
9 2002
DOI
10.5694/j.1326-5377.2002.tb04807.x
ISSN
0025-729X